ArticleOncoTargets and therapy2020

The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia.

Shan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.